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Abstract
The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2, has devastated health
infrastructure around the world. Both ACE2 (an entry receptor) and TMPRSS2 (used by the
virus for spike protein priming) are key proteins to SARS-CoV-2 cell entry, enabling progres-
sion to COVID-19 in humans. Comparative genomic research into critical ACE2 binding
sites, associated with the spike receptor binding domain, has suggested that African and
Asian primates may also be susceptible to disease from SARS-CoV-2 infection. Savanna
monkeys (Chlorocebus spp.) are a widespread non-human primate with well-established
potential as a bi-directional zoonotic/anthroponotic agent due to high levels of human inter-
action throughout their range in sub-Saharan Africa and the Caribbean. To characterize
potential functional variation in savanna monkey ACE2 and TMPRSS2, we inspected
recently published genomic data from 245 savanna monkeys, including 163 wild monkeys
from Africa and the Caribbean and 82 captive monkeys from the Vervet Research Colony
(VRC). We found several missense variants. One missense variant in ACE2 (X:14,077,550;
Asp30Gly), common in Ch. sabaeus, causes a change in amino acid residue that has been
inferred to reduce binding efficiency of SARS-CoV-2, suggesting potentially reduced sus-
ceptibility. The remaining populations appear as susceptible as humans, based on these
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criteria for receptor usage. All missense variants observed in wild Ch. sabaeus populations
are also present in the VRC, along with two splice acceptor variants (at X:14,065,076) not
observed in the wild sample that are potentially disruptive to ACE2 function. The presence
of these variants in the VRC suggests a promising model for SARS-CoV-2 infection and vac-
cine and therapy development. In keeping with a One Health approach, characterizing
actual susceptibility and potential for bi-directional zoonotic/anthroponotic transfer in
savanna monkey populations may be an important consideration for controlling COVID-19
epidemics in communities with frequent human/non-human primate interactions that, in
many cases, may have limited health infrastructure.
Introduction
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in
China in December 2019 has since led to a devastating human pandemic of COVID-19 [1],
the potentially fatal respiratory disease resulting from infection with the novel coronavirus [2].
Due to the ongoing severity of the pandemic in humans, little attention has yet focused on
human/animal transmission beyond the initial presumed zoonotic event with a bat and/or
pangolin host [3]. Although potential anthroponotic transmissions to domesticated animals
has been detected, these transmissions have been relatively rare (e.g., ferrets, cats, dogs) [4]
and human-to-human transmission is the primary risk [5] [6]. Aspects of the biology of
SARS-CoV-2 infection call for stricter scrutiny of such transmissions among non-human pri-
mates kept as pets, among wild non-human primates, and other populations that may have fre-
quent exposure to potentially infected humans.
The angiotensin-converting enzyme 2 (ACE2), previously identified as the key receptor for
the SARS coronavirus [7], has since also been identified as one of the key binding receptors by
which SARS-CoV-2 gains entry to cells [8] [9] [10]. The spike protein of SARS-CoV-2 contains
a variable receptor binding domain (RBD) which binds to the ACE2 receptor facilitating entry
of the virus into cells. Mutations at critical sites in the RBD appear to alter the binding affinity
to ACE2 receptors, facilitating spill-over events into other species. SARS-CoV-2 likely origi-
nated in bats with zoonotic spill-over, via an intermediate host, to humans [3] [11]. In the
same way that mutations in the spike protein have altered binding efficacy to the ACE2 recep-
tor, evidence suggests that mutations or natural variants in the ACE2 receptor may influence
susceptibility or resistance of a species to infection. Identifying key receptors associated with
infectivity and transmission will be important for understanding host range and potentially
susceptible hosts. It has been shown that changes in key residues of ACE2 influence the recep-
tor efficiency and consequently entry of severe acute respiratory syndrome coronavirus 1
(SARS-CoV) into cells [12]. To gain insight into host range for SARS-CoV-2 based on receptor
usage, alignment of predicted amino acid sequences for human, non-human primates and
selected domestic animals showed shared identity at binding regions and critical residues [13].
Recent research has supported the idea that, due to ACE2 receptor congruence–particularly
at critical binding sites for the SARS-CoV-2 spike receptor binding domain–catarrhine pri-
mates may be as susceptible to infection with COVID-19-like disease as humans [13] [14] [15],
presenting the possibility of bi-directional human-non-human primate infections in areas
with human-wildlife contact. Although rhesus macaques (Macaca mulatta) have been experi-
mentally infected and do show COVID-19-like symptoms upon infection [16] [17] [18] zoo-
notic/anthroponotic potential in wild populations has not yet been investigated. This is cause
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for great concern, not just from a global and community health perspective, but also from a
conservation perspective, as many critically endangered non-human primates may also be vul-
nerable to COVID-19 [14].
Cell entry is facilitated by binding of SARS-CoV-2 to ACE2 receptors and on spike protein
priming by host cell proteases. Transmembrane serine protease 2 (TMPRSS2) is a cellular pro-
tease that had previously been shown to be a proteolytic activator of both SARS-CoV and Mid-
dle East respiratory syndrome coronavirus (MERS-CoV), responsible for cleaving the spike
protein of each into a conformation that facilitates cell membrane fusion and increases infec-
tivity [19] [20]. TMPRSS2 also cleaves the ACE2 binding site itself, which further increases
coronavirus infectivity [21]. It has since been shown to similarly prime SARS-CoV-2 for infec-
tion [22]. As in SARS-CoV [20], a TMPRSS2 inhibitor has been shown to block SARS-CoV-2
from cellular entry, and may serve as a treatment for COVID-19 [10]. This suggests that key
polymorphisms in TMPRSS2 protein structure might also yield differential susceptibility to
infection with SARS-CoV-2. This gene region shows pleiotropy in primates, and has previ-
ously shown signs of positive selection across the order while investigating its putative role in
influencing the properties of seminal fluid [23]. Androgens regulate expression of TMPRSS2,
and its functionality is autocatalyzed by cleavage of the protein at the R255 residue, yielding
the functional form [24]. Previous research has identified the proteolytic activation function of
TMPRSS2 to be dependent on the coordination of a catalytic triad comprised of the H296,
D345, and S441 residues [20].
Savanna monkeys (Chlorocebus spp.) are a catarrhine primate that is ubiquitous throughout
sub-Saharan African savanna environments [25]. They are often characterized as problem ani-
mals within this range due to their easy co-habitation with human settlements ranging from
rural farmland to densely packed urban areas [26] [27] [28]. Green monkeys (Ch. sabaeus) are
also endemic to the Caribbean islands of St. Kitts, Nevis, and Barbados, having been brought
to the islands over 300 years ago [29], where they are densely populated and have frequent con-
tact with humans [27]. The established Caribbean populations have since spread to the islands
of St. Martin/St. Maarten and Tortola as escaped pets [30]. There is also a small feral popula-
tion of green monkeys established near Ft. Lauderdale, Florida, in the United States [31].
Savanna monkeys have been shown to be more susceptible than rhesus macaques to respi-
ratory infection and viral replication when exposed to coronavirus SARS-CoV, but when
infected they show no evident external symptoms of disease [32]. Green monkeys (Ch.
sabaeus) exposed to SARS-CoV (Urbani strain) via intratracheal swab have high titers of the
virus in tracheal and lung tissue accompanied by pneumonitis on days 2 through 4 of infec-
tion, followed by eventual resolution [32]. Given the increased severity of response to SARS-
CoV in savanna monkeys compared to rhesus, recent evidence that rhesus macaques show
COVID-19-like symptoms upon SARS-CoV-2 infection [16] [17] [18] strongly suggests that
savannah monkeys will also respond to infection with COVID-19-like disease. This not only
raises the potential of the savanna monkey as a potential model for developing vaccines and
therapeutics against COVID-19, but also for anthroponotic and zoonotic infection where
savanna monkeys and humans meet.
Contact between savanna monkeys and humans with transmissible COVID-19 infections
seem an inevitability, even with social distancing and stay-at-home orders in place in many
African and Caribbean nations showing high infection rates. This is primarily due to their fre-
quent raiding of crops and interactions with human refuse and other potential fomites in the
wild [26] [27] [33]. Use of human resources as ‘hotspots’ of interest could potentially exacer-
bate animal disease propagation in human-frequented areas [34]. Urban areas present a special
risk, as urban savanna monkeys are more habituated to human proximity and less likely to flee
when humans are near [35]. Indeed, several zoonoses and anthroponoses have already been
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documented to pass between humans and wild savanna monkeys throughout their range (e.g.,
simian foamy virus [36], Staphylococcus aureus [37], gastrointestinal parasites [38]). The abun-
dance of sanctuary and rehabilitation centers that focus on caring for those savanna monkeys
that have been adversely affected by human impacts serves as another key mediator of poten-
tial transmission [39] [40] [41].
Given the high zoonotic/anthroponotic transmission potential between savanna monkeys
and humans, we used recently published genome sequence data from 163 wild savanna mon-
keys [42] and 82 captive green monkeys from the Vervet Research Colony (VRC) at Wake For-
est School of Medicine [43] to document variation in the ACE2 and TMPRSS2 gene regions in
this widespread genus. Our goals were 1) to assess the likelihood of anthroponotic infection of
wild savanna monkeys upon exposure to infected humans, in order to evaluate the risk of
savanna monkey populations becoming 2a) as highly impacted as human populations by
potential epidemics, 2b) vectors of infection to humans via zoonotic exposure and 2c) potential
reservoirs of infection with potential for the post-pandemic initiation of novel COVID-19 out-
breaks among humans; 3) identify natural genetic models for functional studies of the host
proteins critical to SARS-CoV-2 entry in the context of transmission of the virus and develop-
ment of treatments for COVID-19; and 4) assess if captive savanna monkey colonies might be
appropriate for modeling COVID-19 disease infection and therapeutics studies, as with
SARS-CoV.
Materials and methods
Whole genome sequence data (median 4.4X coverage, with at least one member per taxon
sequenced to at least 10X coverage) was previously generated for 163 individual wild savanna
monkeys as part of research conducted by the International Vervet Research Consortium (for
details, see [42] [44]. Raw sequence data were aligned to the Vervet-AGM reference assembly
(ChlSab1.1 [45]), and variant calls are archived and publicly available online via Ensembl
(Release 99 [46]). These data include resequencing from populations across sub-Saharan
Africa and the Caribbean, including: 16 grivets (Ch. aethiops) from Ethiopia; 14 vervets (Ch.
pygerythrus hilgerti) from Kenya and Tanzania; 16 malbroucks (Ch. cynosuros) from Zambia;
51 vervets (Ch. pygerythrus pygerythrus) from South Africa and Botswana; 11 tantalus monkeys
(Ch. tantalus) from the Central African Republic; and 63 African green monkeys (Ch.
sabaeus), 22 from The Gambia, 2 from Ghana, 34 from St. Kitts & Nevis, and 5 from Barbados
[42]. Although the taxonomy of these populations is contentious and currently unresolved
[25], for simplicity we have here chosen to follow the taxonomic designations of Groves [47].
Variant calls in in the ACE2 (X:14,030,233–14,077,785) and TMPRSS2 (2:85362117–85412926)
gene regions in wild savanna monkeys were inspected using the Variant Table function, and
filtered by annotations produced by Ensembl genebuild [48].
Allele frequencies in the VRC monkeys are reported here for 82 monkeys with moderate to
high sequencing coverage depth (10-30X). Variant discovery and genotype calling steps are
described in detail by Ramensky et al. [43]. For variant annotation, we used Ensembl Variant
Effect Predictor [49]. Sequenced monkeys in the VRC are highly related, so in this case MAF
should be interpreted as alternative allele occurrence rather than frequency in the strict statisti-
cal sense, which implies independent observations.
Finally, we used SSIPe [50] to assess the change in protein binding affinity caused by the
discovered Asp30Gly mutation at the critical residue identified via alanine scanning mutagen-
esis analyses performed by Melin et al. [14]. The change in free energy due to the mutation
was inferred by comparing against a reference interaction of human ACE2 receptor bound to
the SARS-CoV-2 spike receptor binding domain (PBD 6M0J).
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Results
There is substantial variation in the ACE2 sequence of wild savanna monkeys. None of the
detected variants are predicted to cause frameshifts or premature stops in the transcription
process. Exonic variants include 6 missense variants, 14 synonymous variants, and two poten-
tial canonical splice region variants (Table 1), which are the only examples of putative protein-
truncating variants in the vervet ACE2 discovered so far. Other detected variants include 43 in
the 3’ UTR region, and 680 intronic variants including 3 potential splice region variants. Mis-
sense variants in savanna monkeys appear to occur only in the Ethiopian Ch. aethiops and
West African/Caribbean Ch. sabaeus populations sampled. Only one of the missense-mediated
changes in amino acid residues, also in Ch. sabaeus (X:14,077,550; Asp30Gly), involves a con-
version at one of the critical binding sites for SARS-CoV-2 identified by Melin et al. [14]. This
substitution is predicted to destabilize the binding of SARS-CoV-2 to ACE2 receptors
(ΔΔGbind = 0.958 kcal/mol), and of all the point mutations analyzed in a recent survey of pri-
mates [14], Asp30Gly reduces the predicted binding affinity more than all but the Tyr21His
variant, which is found in most strepsirrhines (lemurs and lorisoids) and all platyrrhines
(monkeys from the Americas) considered.
Table 1. Potential functional variants in ACE2 gene region sequence among wild savanna monkeys.
Position Variant Consequence AAFa AA PosAA Notes
X:14035311 T/C Missense 0.09 I/V 753 Alt. allele prevalent in Ethiopia (AAF = 0.94); absent in all others
X:14035353� C/T Missense 0.33 V/I 739 Alt. allele only in Ch. sabaeus (AAF = 0.75–1; AAFVRC = 0.84).
X:14035354 G/A Synonymous 0.09 P 738 Alt. allele prevalent in Ethiopia (AAF = 0.94); absent in all others
X:14035357 G/A Synonymous 0.02 S 737 Alt. allele only found in Ethiopia (AAF = 0.16)
X:14035374� T/C Missense 0.97 I/V 732 Ref. allele only found in St. Kitts (AAF = 0.75; AAFVRC = 0.85).
X:14041898 T/C Synonymous 0.13 G 629 Alt. allele only found in southern Africa (AAF = 0.36–1.00)
X:14043283 G/C Synonymous 0.04 L 585 Alt. allele predominantly found in Central African Republic (AAF = 0.36)
X:14043289� T/G Synonymous 0.06 P 583 AAFVRC = 0.01
X:14043304 G/A Synonymous 0.03 N 578 Alt. allele only found in South Africa (AAF = 0.10)
X:14043773 T/A Intronic SRV 0.45 - - Fixation of minor allele in Ch. sabaeus
X:14043797 T/A Missense 0.02 E/V 549 Alt. allele only found in Ethiopia (AAF = 0.19)
X:14045023� C/G Missense 0.62 E/D 483 Ref. allele near fixation in Ch. sabeaus (AAF = 0.00–0.50; AAFVRC = 0.01).
X:14049928 G/A Synonymous 0.01 I 358
X:14052949 A/G Synonymous 0.18 F 315 Alt. allele only found in southern Africa (AAF = 0.22–0.52)
X:14061092 C/T Intronic SRV 0.02 - - Alt. allele only present in The Gambia (AAF = 0.14)
X:14063390 A/G Synonymous 0.02 L 266 Alt. allele only found in Ethiopia (AAF = 0.22)
X:14064963 C/T Synonymous; SRV 0.02 E 232 Alt. allele only present in The Gambia (AAF = 0.14)
X:14065002 G/A Synonymous 0.01 R 219 Alt. allele only present in East Africa (AAF = 0.13–0.25)
X:10465076 C/CT CT/C Splice Acceptor 0.08 0.34 - - Only present in the VRC, expected to be deleterious.
X:14067819 T/C Intronic SRV 0.04 - - Alt. allele only found in southern Africa (AAF = 0.03–0.13)
X:14077504 A/G Synonymous 0.02 L 45 Alt. allele only present in Ethiopia (AAF = 0.25)
X:14077524� A/G Synonymous 0.61 L 39 Fixation of reference allele in Ch. sabaeus (AAFVRC = 0.01)
X:14077531 G/A Synonymous 0.01 A 36 Alt. allele only present in Zambia (AAF = 0.06)
X:14077550� T/C Missense 0.13 D/G 30 Alt. allele only found in Ch. sabaeus (AAF = 0.01–1.00; AAFVRC = 0.36)
Emboldened, shaded text indicates coding regions or residues critical to SARS-CoV-2 binding. AAF = alternative allele frequency for the full sample. AA = change in
amino acid residue predicted to accompany sequence variation. PosAA = amino acid position in the protein. SRV = splice region variant. Asterisks (
�) = variant also
present in the Vervet Research Colony at Wake Forest School of Medicine. AAFVRC = alternative allele frequency in the VRC.
aFor population-specific values of AAF see S1 Table.
https://doi.org/10.1371/journal.pone.0235106.t001
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Savanna monkeys in the extended pedigree of Caribbean-origin Ch. sabaeus in the VRC
showed marked variation in ACE2. A total of eight ACE2 variants are segregating in the pedi-
gree: 2 splice acceptor site variants, 4 missense variants, and 2 synonymous variants. The two
splice acceptor site variants are located at X:14,065,076 (at the end of a polyT tract) and were
not observed in the wild monkeys. Both variants are common in the VRC (AAFVRC = 0.08 and
AAFVRC = 0.34), and both are expected to be protein truncating variants with potential delete-
rious effects on the protein. These novel variants might have emerged in the VRC as de novo
mutations, or may be present in wild populations at very low frequencies not captured with
our moderate sample sizes. That the VRC pedigree is founded from a relatively small number
of individuals, themselves originating from the founder population on St. Kitts, followed by
the expansion of the pedigree might have led to an increased frequency of such rare variants.
All four missense variants observed in wild Ch. sabaeus (X:14,035,353, X:14,035,374,
X:14,045,023, and X:14,077,550 causing Asp30Gly) are also present the VRC.
We also examined the genetic variation in TMPRSS2 both in the wild populations and VRC
(S2 and S3 Tables). A total of 15 missense and 21 synonymous variants were observed in the
wild populations. In the VRC, one missense, one splice region and 9 synonymous variants
were identified, including several variants shared with the East, Central, and South African
populations, and all Ch. sabaeus variants (all of which are synonymous) observed in the wild
populations, except one rare variant found in the Gambian population. An additional missense
variant and splice variant were observed only in the VRC. Although there is substantially more
variation in TMPRSS2 compared to ACE2 among savanna monkeys, all retain the functional
residues for the cleavage site (R255) and for the catalytic triad (H296, D345, and S441).
Discussion
The results of this first investigation of SARS-CoV-2 susceptibility in savanna monkeys in
both the wild populations and in the VRC pedigree suggest that there are population differ-
ences in ACE2 sequence variation among savanna monkeys, some of which are estimated to
yield changes in amino acid residues or exert deleterious effects on the transcript and protein
function. The majority of the variants observed in this study in the wild monkeys are unlikely
to dramatically alter susceptibility to disease upon exposure to SARS-CoV-2. The lack of
frameshift mutations is in agreement with the paucity of protein-truncating variants in the
human ortholog observed in gnomAD population data, apparently reflecting the intolerance
of this gene against this type of variation in humans [51]. One of these changes (X:14077550;
Asp30Gly) occurs at a previously identified critical binding site, part of the SARS-CoV-2 spike
receptor binding domain [14]. A similar variant at this site (Asp30Glu, E30) is seen in the
Microcebus murinus reference genome, and is predicted to confer reduced binding affinity of
SARS-CoV-2 to ACE2 receptors (ΔΔGbind = 0.692 kcal/mol) [14]. The Asp30Gly mutation,
found in West African savanna monkeys and their Caribbean descendant populations (more
commonly called African green monkeys, Ch. sabaeus), is predicted to destabilize the bond
between the virus and the receptor to a greater degree (ΔΔGbind = 0.958 kcal/mol). This sug-
gests that a sizable proportion of the populations of Ch. sabaeus in West Africa and the Carib-
bean, those possessing the G30 residue (see S1 Table for population-specific details on
prevalence), may have reduced susceptibility to SARS-CoV-2 infection and developing
COVID-19-like illness.
Given the lack of clear impact on known functional regions in TMPRSS2, it remains to be
seen what effect, if any, the population-specific missense variants observed might have on
SARS-CoV-2 susceptibility. That expression of TMPRSS2 is dependent on androgen (AR)
expression [24], however, may explain why human males appear to show significantly higher
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mortality with COVID-19 [52]. We might expect to see a similar, sex-specific pattern of sever-
ity in non-human primates. That male savanna monkeys are often bolder than females [53]
suggests that they may both be more likely to interact with humans and more vulnerable to
severe outcomes from SARS-CoV-2 infection.
Overall, our analysis suggests that savanna monkeys are likely susceptible to SARS-CoV-2
infection, though some populations–notably, those African green monkeys (Ch. sabaeus) with
the Asp30Gly variant–may possess additional resistance to the disease, and that bi-directional
infections between humans and savanna monkeys are possible. This high probability for sus-
ceptibility suggests that, as in other infected non-human primates (e.g., rhesus macaques) [16]
[17] [18], savanna monkeys will likely become ill upon contracting the disease, and, like
macaques, may suffer similar symptoms while being infectious to humans. Although this
means there is high potential for savanna monkeys to experience concurrent outbreaks of
COVID-19-like illness with sympatric human populations, they are unlikely to serve as a long-
term reservoir of the disease, and may be less susceptible in the case of re-infection [32]. Addi-
tionally, strict quarantines in response to epidemics in nations with high contact between
savanna monkeys and humans, like those implemented in March and April of 2020 in South
Africa [54], will likely prevent such bi-directional transmissions from occurring as they will
also isolate humans from non-human primate populations. Although personal protective
equipment is the norm in captive primate facilities and many rescue centers and sanctuaries,
similar isolation measures should be considered among those populations when human infec-
tion is likely.
We acknowledge that identifying susceptibility or resistance to infection based on receptor
usage has limitations, especially with regards to describing severity of disease which has multi-
ple contributing factors, for example the role of inflammatory cytokine responses in immuno-
pathogenesis [55]. However, receptor usage provides an indication of species that could
potentially be susceptible [11] [14]. The close proximity of humans and wild non-human pri-
mates provides potential for cross-species transmission of pathogens, and for some endan-
gered species this could have devastating effects [14]. Similarly, identifying if non-human
primates have the potential to act as intermediates hosts, as for Ebola virus [56], would be
important for understanding zoonotic transmission and use of animal models.
Clear steps that must be taken to better understand this potential threat include characteriz-
ing the clinical signs of SARS-CoV-2 infection in savanna monkeys, and assessing whether
they can develop a COVID-19-like disease state as seen in rhesus macaques. Established cap-
tive research colonies, such as those at the Vervet Research Colony of the Wake Forest School
of Medicine in the United States (Ch. sabaeus), the St. Kitts Biomedical Research Foundation
in St. Kitts & Nevis (Ch. sabaeus), and the Medical Research Council in South Africa (Ch.
pygerythrus pygerythrus), would be ideal for such assessments [25] [44]. These colonies may
also be critical to the establishment of vaccines and therapies for COVID-19 should the green
monkeys serve as a better model of SARS-CoV-2 infection and symptoms than macaque mod-
els, as is the case with SARS-CoV [32].
To facilitate such assessments, we characterized ACE2 and TMPRSS2 variation in the Ver-
vet Research Colony. All four missense variants present in the wild Ch. sabaeus populations,
including the potential modifying variant Asp30Gly (AAFVRC = 0.36) are segregating in the
VRC. The monkeys in the VRC may be useful models for better understanding variable sus-
ceptibility to infection with SARS-CoV-2 and developing appropriate interventions in these
nonhuman primate populations. Human data collected so far lacks common natural muta-
tions conferring differing efficiencies in coronavirus S-protein binding [57]. From this per-
spective, a model species with natural genetic variation with potential modulatory effects on
the ACE2 role in the SARS-CoV-2 infection is of particular interest. In the VRC, we observed
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two splice acceptor variants potentially resulting in the truncation of the ACE2 protein. While
they may provide a potential natural model for studies of the pathomechanism of the SARS-
CoV-2 infection, they should be treated with caution as these variants are located in the repeti-
tive region and require further validation through genotyping animals of interest.
Efforts should also be made to sample widely from wild savanna monkeys–with a focus on
those in close contact with humans–in order to assess whether the virus has infected wild pri-
mate populations, and what characteristics of the local environment are important to human-
monkey transmission. Researchers affiliated with the International Vervet Research Consor-
tium already have contacts and protocols in place to potentially conduct such research in
St. Kitts & Nevis, South Africa, and The Gambia [25] [44]. Such assessments could best charac-
terize whether anthroponotic/zoonotic transfer of SARS-CoV-2 is a genuine public health and
conservation concern, and predict areas where risk is high for such transmission. This work
could better inform local policy with respect to human wildlife interactions. These steps will be
essential to assess the potential risk of COVID-19 outbreaks mediated by human-monkey con-
tact or conflict with savanna monkeys in Africa and the Caribbean.
Such assessments are critical, and would be the first steps towards a One Health approach
to future monitoring of SARS-CoV-2 [58] [59]. Savanna monkeys predominantly live in
nations with generally moderate health infrastructure, which have rapidly prepared but are
also predicted to be among the hardest-hit by the current pandemic [60] [61]. Previous cycles
of zoonotic disease transmission have already been well-established for other fatal outbreaks in
such settings, in non-human primates with significantly lower frequencies of human interac-
tion (e.g., wild apes and Ebola [55]). A clear understanding of potential coincident outbreaks
and zoonotic cycles, especially in highly human impacted non-human primate populations,
may be important to the long-term management of SARS-CoV-2 in both human health and
conservation contexts.
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